Business Context and Reporting Period
Company: IGC Pharma, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: June 5, 2026
Event: Entry into a Material Definitive Agreement regarding the extension of a Master Loan and Security Agreement with O-Bank Co., Ltd.
Key Financial Metrics
This filing does not report revenue, profit, cash flow, margins, or liquidity positions. It focuses exclusively on debt facility terms.
- Debt Facility Limit: $12,000,000 (Maximum aggregate limit)
- Facility Fee (2026): $60,000
- Facility Fee (2025): $48,000
Material Changes Versus Prior Period
The Company extended its existing Master Loan and Security Agreement with O-Bank Co., Ltd. The material terms remain substantially unchanged from the facility letter dated June 24, 2025, with the following exception:
- Fee Increase: The facility fee increased from $48,000 to $60,000.
Guidance, Outlook, and Risks
The filing contains no management guidance, outlook, or specific risk factors beyond the standard incorporation of the full Loan Agreement text. The agreement is incorporated by reference as Exhibit 10.1.
Investor Verification Checklist
- Review the full text of the 2026 O-Bank General Banking Facility Letter (Exhibit 10.1) for covenants and repayment terms.
- Verify the Company's current drawdown status against the $12,000,000 facility limit.
- Confirm the impact of the increased facility fee on future operating expenses.